Axsome Therapeutics (AXSM) Valuation Check After Recent Share Price Cooling [Yahoo! Finance]
Axsome Therapeutics, Inc. (AXSM)
Last axsome therapeutics, inc. earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
axsome.com
Company Research
Source: Yahoo! Finance
Axsome Therapeutics: Stock Snapshot After Recent Moves Axsome Therapeutics (AXSM) has drawn fresh attention after recent trading, with the share price closing at US$156.35 and showing mixed returns over the past week, month, and past 3 months. Investors are weighing this performance against the company's focus on central nervous system treatments, its current US$7.998b market value, and its reported annual revenue of US$638.496 million alongside a net loss of US$183.174 million. See our latest analysis for Axsome Therapeutics. While the share price has slipped in the short term, including a 1-day share price return decline of 4.82% and a 30-day share price return decline of 4.6%, the 1-year total shareholder return of 34.06% and 5-year total shareholder return of 174.30% suggest longer term investors have still seen substantial gains. This indicates momentum that has cooled recently rather than disappeared. If Axsome has you looking more closely at healthcare and AI, it can
Show less
Read more
Impact Snapshot
Event Time:
AXSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXSM alerts
High impacting Axsome Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AXSM
News
- Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric ConditionsGlobeNewswire
- Axsome Therapeutics (AXSM) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
- Axsome Therapeutics (AXSM) had its price target raised by Guggenheim from $220.00 to $245.00. They now have a "buy" rating on the stock.MarketBeat
- This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain [Yahoo! Finance]Yahoo! Finance
- Axsome Therapeutics Highlights Auvelity's $500M+ Run, FDA Catalyst and Late-Stage Pipeline at Conference [Yahoo! Finance]Yahoo! Finance
AXSM
Earnings
- 2/23/26 - Beat
AXSM
Sec Filings
- 4/1/26 - Form 8-K
- 3/26/26 - Form SCHEDULE
- 2/27/26 - Form 4
- AXSM's page on the SEC website